Estelle Haenel has joined Kayentis as Medical Director. She will help leverage the company’s growing medical expertise bringing to Kayentis her extensive experience in clinical trials.
Estelle has more than 20 years’ experience in the Pharmaceutical Industry, in both pre-clinical and clinical research. Estelle joined Pfizer in early 2012 after having worked for other Big Pharma and Biotech companies. She has led projects from Phase 1 through 4 in multiple therapeutic areas, providing solid experience in clinical science and clinical operations, as well as a good understanding of the complexity of the regulatory environment. Estelle has also robust expertise in non-interventional clinical research and clinical pharmacology.
“I am very excited to join a growing company such as Kayentis encompassing innovation, science, and patient engagement at the heart of its strategy, as well as commitment, team work, and customer focus as core values. I am very keen to contribute to enhancing the quality of life of patients around the globe through optimized, targeted eCOA services.” said Estelle Haenel, Kayentis’ Medical Director
“I’m pleased to welcome Estelle as Medical Director. With her expertise in multiple therapeutic areas as well as extensive experience in clinical research, she will enrich our scientific expertise as well as enhance the quality of our services for the benefit of patients, healthcare providers, and clinical site staff.” said Guillaume Juge, Kayentis’ CEO
Graduated from:
- Kremlin Bicêtre University – Paris – PhD in molecular and cellular biology
- René Descartes University – Paris – PharmD
Recent Publications and presentations
- Publication (2018): A Long-term Safety Study of Latanoprost in Pediatric Patients with Glaucoma and Ocular Hypertension: A Prospective Cohort Study
American Journal of Ophthalmology, 2018
- Presentation (2017): Evolution of strategic partnership: small shift or true evolution?
Pharma Outsourcing & Partnerships, London
Scientific Research PUBLICATIONS and PRESENTATIONS (under Maiden name Estelle Guitard)
Publications
- “G3BP is overexpressed in human tumors and promotes S phase entry”
Estelle Guitard, Fabienne Parker, Régine Million, Joseph Abécassis and Bruno Tocqué.
- “Identification of G3BPh, a new RNA binding protein homologous to G3BP, at the crossroad between signaling and RNA metabolism”
Estelle Guitard, Derek Kennedy, Jean-Michel Itier, Bruno Tocqué, John Mattick and Fabien Schweighoffer.
Submitted to BBRC in 2000.
- “Sam68 is a RasGAP associated protein in mitosis”
Estelle Guitard, Isabelle Barlat, Florence Maurier, Fabien Schweighoffer and Bruno Tocqué.
Biochemical and Biophysical Research Communications, 1998;245,2:562-566.
- “A role for Sam68 in cell cycle progression antagonized by a splice variant within the KH domain”
Isabelle Barlat, Florence Maurier, Marc Duchesne, Estelle Guitard, Bruno Tocqué and Fabien Schweighoffer.
The Journal of Biological Chemistry 1997:272,6:3129-3132.
Poster communications
- “G3BP is overexpressed in human tumors and promotes S phase entry”
Estelle Guitard, Fabienne Parker, Régine Million, Joseph Abécassis and Bruno Tocqué.
Congress: Signal transduction pathways and regulation of gene expression as therapeutic targets, Luxembourg, January 2000.
- “G3BP and G3BPh, at the crossroad between signaling molecules and RNA metabolism”
Estelle Guitard, Derek Kennedy, Jean-Michel Itier, Isabelle Barlat, Bruno Tocqué, John Mattick and Fabien Schweighoffer.
Congress: La phosphorylation des protéines de la SFBBM in Arcachon, France, October 1998.
- “Sam68 is a RasGAP associated protein in mitosis”
Estelle Guitard, Isabelle Barlat, Florence Maurier, Fabien Schweighoffer et Bruno Tocqué.
Congress: Transduction du signal et oncogènes in Arcachon, France, October 1997.
Congress: International meeting on oncogenes at Fredericks, Maryland, US, June 1997.
